OR WAIT null SECS
Cambrex has completed the expansion of its North Carolina facility, doubling its manufacturing capacity.
Global contract development and manufacturing organization (CDMO), Cambrex, has doubled its manufacturing capacity with an expansion of its facility in High Point, North Carolina. The completion of the expansion was announced by the company in an Oct. 2, 2023 press release.
The $38 million expansion has added new state-of-the-art analytical and chemical development laboratories, two new clinical manufacturing suites, and a small-scale commercial manufacturing operation comprising three work centers and 2000 L reactors to the High Point facility. Additionally, with the added infrastructure, Cambrex has created more than 70 new positions and is seeking to recruit expert pharmaceutical R&D scientists and staff within the region.
“When we began this project in 2021, our vision extended far beyond capacity,” said Tom Loewald, CEO, Cambrex, in the press release. “We designed a facility that can continue to deliver on client needs as the industry evolves, with state-of-the-art technology and laboratory equipment, an energy-efficient infrastructure, and clinical to commercial manufacturing scale.”
“We are extremely excited about this expansion in North Carolina, which would not have been possible without the support of the State’s leadership and economic development programs, and their focus on nurturing the region’s skilled and diverse workforce,” added Dan Bowles, vice president and general manager, Cambrex High Point, in the press release.
Furthermore, the newly expanded High Point facility provides complementary capabilities to those of Snapdragon Chemistry—which Cambrex had previously acquired in January 2023. Snapdragon Chemistry specializes in R&D for API batch and continuous flow process design, meaning that the combination of those capabilities along with the new offerings available at High Point will provide customers with a single-vendor offering for their flow chemistry scale-up needs through to commercialization.